Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a paper he co-authored published on ESMO Open on LinkedIn:
“New publication in ESMO Open!
A study led by colleagues at Dana-Farber Cancer Institute (Stefania Morganti, Sara Tolaney, Antonio Giordano) has just been published:
‘Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer’
This work analyzed real-world outcomes with sacituzumab govitecan in more than 121 patients with metastatic breast cancer (both TNBC and HR+/HER2-). Results confirm the modest benefit of this ADC in heavily pretreated disease, consistent with registrational trials.
Importantly, DNADX ctDNA-based subtypes were significantly associated with survival outcomes. Patients with TF-low tumors experienced the best prognosis, whereas proliferative and basal-related subtypes fared worse. This reinforces the value of ctDNA-based molecular stratification in the ADC era.
We are proud that REVEAL GENOMICS, Clínic Barcelona Comprehensive Cancer Center, contributed to this collaborative effort, together with Vall d’Hebron Institute of Oncology (VHIO) and Gustave Roussy.
Congratulations to our Dana-Farber Cancer Institute colleagues for leading this important study!”
Title: Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
Authors: S. Morganti, R.J. Kusmick, M.E. Hughes, F. Brasó-Maristany, K. Smith, P. Tarantino, R. Vega-Leon, T. Grinda, F. Pardo, K. Dvir, G.L. Suggs, S. Buck, M. Skeffington, A.C. Garrido-Castro, H.A. Parsons, S.L. Sammons, A. Prat, N.U. Lin, S.M. Tolaney, A. Giordano
Read further on ESMO Open.
More posts featuring Aleix Prat on OncoDaily.